# Telogen Effluvium

Evaluate diffuse shedding by anchoring onset to a trigger, excluding patterned and inflammatory alopecia, and correcting identifiable systemic, nutritional, or medication causes. Acute telogen effluvium usually resolves after trigger removal; shedding beyond 6 months warrants reassessment for chronic disease or a competing diagnosis.

**Clinical question:** How should clinicians diagnose, investigate, and manage acute or chronic telogen effluvium?

Updated: 2026-09-15T23:50:19.604078+00:00

## What matters in practice
- Diffuse shedding beginning about 2-3 months after febrile illness, surgery, delivery, weight loss, medication exposure, or other physiologic stress strongly supports acute telogen effluvium; persistence beyond 6 months defines chronic shedding and should prompt renewed etiologic and diagnostic assessment. [8][13][16]
- Do not diagnose chronic telogen effluvium until competing causes of diffuse alopecia, particularly androgenetic alopecia, diffuse alopecia areata, thyroid disease, iron deficiency, nutritional disturbance, and medication-related loss, have been considered. [3][4][12]
- Scalp biopsy is most useful when diffuse shedding persists beyond 6 months or clinical examination and trichoscopy cannot distinguish chronic telogen effluvium from androgenetic alopecia or diffuse alopecia areata. [4][17]
- Management is trigger-directed: replace or discontinue a suspected causative drug when clinically feasible, treat documented systemic or nutritional disease, and set expectations that acute shedding is usually self-limited. [16][17]
- Topical minoxidil is commonly used but has not been proven to promote recovery in telogen effluvium; avoid presenting it as required therapy for an otherwise self-limited acute episode. [6][15]

## Identify the shedding pattern and decide whether telogen effluvium is plausible

Use chronology and distribution before ordering broad laboratory panels.

Classify the presentation as acute when diffuse shedding has lasted less than 6 months and chronic when it persists beyond 6 months. Acute telogen effluvium typically begins 2-3 months after a trigger, although diffuse shedding may present 1-6 months after a precipitating event. High-yield exposures include febrile or severe systemic illness, major surgery, childbirth, pregnancy-related events, weight loss or caloric restriction, emotional or physiologic stress, thyroid disease, medications, and nutritional disturbance. [7][8][11][16]

A history of more than 100 shed hairs daily or collection of 100 or more hairs over 24 hours supports excessive shedding, but neither measure establishes etiology. Ask specifically about timing of infection, hospitalization, surgery, postpartum hemorrhage, restrictive diets, rapid weight loss, and all prescription, over-the-counter, and hormonal drugs; anticoagulants, anticonvulsants, and high-dose contraceptives are among reported medication associations. [15][18]

The working diagnosis should remain provisional when thinning is patterned, progression is gradual rather than abruptly shedding-predominant, or there is a strong family history of androgenetic alopecia. Androgenetic alopecia is the most common competing diagnosis in diffuse loss and may coexist with telogen effluvium; trichoscopy can help distinguish these entities. [3][24]
- Favor acute telogen effluvium: abrupt diffuse shedding after a plausible trigger, often with visible short frontal regrowth as the episode resolves. [16]
- Reconsider telogen effluvium: shedding with persistent or progressive patterned thinning, a course longer than 6 months, or no satisfactory explanation after directed evaluation. [3][13][17]
- Expand the differential: diffuse alopecia areata, anagen effluvium, systemic disease, hypothyroidism, iron deficiency, zinc deficiency, and protein or caloric restriction can present with diffuse loss. [3][12]

*Clinical branches that change the next diagnostic step. [3][4][12][16][17]*

| Clinical pattern | Most consequential alternative | Next step |
| --- | --- | --- |
| Abrupt diffuse shedding 2-3 months after fever, surgery, delivery, weight loss, or stress; duration <6 months | Acute telogen effluvium | Identify and remove or treat the trigger; provide a time-limited prognosis rather than reflexive hair-growth treatment. [8][16][17] |
| Diffuse shedding persists >6 months or fluctuates over months | Chronic telogen effluvium; repeated triggers; androgenetic alopecia | Reassess medications, nutrition, thyroid and systemic disease; use trichoscopy and consider scalp biopsy when the distinction remains uncertain. [4][13][17] |
| Patterned thinning, strong family history, or suspected follicular miniaturization | Androgenetic alopecia, with or without concurrent telogen effluvium | Use trichoscopy; obtain biopsy if the diagnosis will alter management and clinical findings remain equivocal. [3][4] |
| Diffuse loss without a clear trigger or with atypical clinical findings | Diffuse alopecia areata, anagen effluvium, systemic or nutritional alopecia | Direct testing to the history and examination; biopsy when diffuse alopecia areata or another competing diagnosis cannot be excluded clinically. [3][4][12] |

## Use targeted testing to find reversible causes, not to confirm telogen effluvium

No serum laboratory marker reliably diagnoses telogen effluvium.

Obtain testing when the history or examination identifies a plausible reversible branch: thyroid disease, blood loss or inadequate iron intake, restrictive dieting or malnutrition, renal or liver disease, or other systemic illness. Thyroid disease, severe iron deficiency anemia, zinc deficiency, and severe protein, fatty-acid, or caloric restriction are recognized causes of diffuse telogen hair loss. [11][12]

Serum ferritin can document iron deficiency, but ferritin is not a stand-alone diagnostic test for telogen effluvium. In one comparative study, mean ferritin in telogen effluvium was 24.27 ng/mL and an optimal discriminating cutoff was 24.45 ng/mL; this finding does not establish a universal treatment target. Proposed ferritin thresholds for hair-loss prevention vary, with >40 micrograms/L used in one study and >15 micrograms/L considered sufficient by some authors. [10][18]

Order ferritin to evaluate suspected iron deficiency rather than treating a marginal value as proof of causation. Evidence linking iron deficiency without anemia to chronic diffuse loss remains controversial; supplementation is most defensible for documented deficiency or a clinical iron-deficiency syndrome rather than indefinite empiric use. [2][12]

A medication review is a diagnostic intervention. When a drug is temporally plausible, weigh substitution or discontinuation against the risk of interrupting essential therapy; do not stop anticoagulants, anticonvulsants, or hormonal agents solely on the basis of shedding without coordinating with the prescribing clinician. Suspected causative drugs should be replaced or discontinued when feasible. [17][18]
- Use ferritin when blood loss, low dietary iron intake, restrictive eating, anemia, or other iron-deficiency risk is present; interpret values in the broader clinical context. [12][18]
- Assess thyroid function when symptoms, history, or medication exposure suggests thyroid disease, because hypothyroidism is a recognized cause of diffuse alopecia. [3][4][12]
- Assess nutritional exposures directly: recent crash dieting, chronic starvation, inadequate protein or caloric intake, and risk factors for zinc deficiency change the cause-directed plan. [12]
- Treat active scalp psoriasis or seborrheic dermatitis when present because scalp inflammatory disease may contribute to ongoing shedding. [17]

*Interpretation of common workup branches in diffuse shedding. [3][10][12][18]*

| Finding or risk factor | Interpretation | Action |
| --- | --- | --- |
| Plausible trigger 2-3 months before abrupt shedding | Supports acute telogen effluvium but does not exclude coexisting androgenetic alopecia. [8][16] | Address the trigger and monitor for reduction in shedding and regrowth. [16][17] |
| Low ferritin with clinical risk for iron deficiency | Confirms iron deficiency when interpreted with the clinical context; the ferritin threshold relevant to hair outcomes is unsettled. [10][12][18] | Treat documented deficiency and investigate the source of iron loss or inadequate intake. [4][12] |
| Thyroid dysfunction | A recognized systemic cause of diffuse hair loss. [3][4][12] | Treat the thyroid disorder and reassess shedding over time. [4] |
| Severe caloric, protein, fatty-acid, or zinc deficiency exposure | Can induce diffuse telogen hair loss. [12] | Correct the nutritional deficiency and discontinue restrictive intake when possible. [12] |
| Normal targeted evaluation with shedding >6 months | Primary chronic telogen effluvium remains possible, but androgenetic alopecia and diffuse alopecia areata require exclusion. [4][13] | Perform trichoscopy; proceed to scalp biopsy if uncertainty persists. [3][4][17] |

## Use trichoscopy and biopsy when chronic diffuse loss could be androgenetic alopecia or alopecia areata

Biopsy is a discriminator, not a routine test for a clear acute episode.

Reserve scalp biopsy for diffuse shedding that lasts longer than 6 months, a discordant history and examination, or persistent uncertainty between chronic telogen effluvium, androgenetic alopecia, and diffuse alopecia areata. Multiple biopsies improve diagnostic accuracy. A biopsy may be necessary because chronic telogen effluvium can overlap clinically with androgenetic alopecia and because diffuse alopecia areata may require exclusion. [4][17]

On scalp biopsy, chronic telogen effluvium shows increased telogen hairs; one review reports an anagen:telogen ratio of approximately 8:1 compared with 14:1 in normal scalp. In a large chronic telogen effluvium series using 4-mm horizontal sections, the mean terminal-to-velluslike ratio was 9:1, with 89% terminal hairs in anagen and 11% in telogen. [5][17]

Follicular miniaturization argues against isolated telogen effluvium and favors androgenetic alopecia. Peribulbar infiltrate also is not expected in uncomplicated telogen effluvium. In the comparative histology series, significant inflammation and fibrosis occurred in 37% of androgenetic alopecia cases versus 10%-12% of chronic telogen effluvium cases and controls. [5][17]
- Do not biopsy a classic, short-duration, trigger-associated acute episode that is already improving unless examination suggests another alopecia. [16][17]
- Biopsy chronic diffuse loss when the result will decide between reassurance and cause-directed management of telogen effluvium versus treatment of androgenetic alopecia or another alopecia. [4][17]
- Interpret pathology with the clinical timeline: chronic telogen effluvium is a diagnosis made after exclusion of other causes of diffuse alopecia. [4]

*Biopsy findings that help separate chronic telogen effluvium from competing diffuse alopecias. [5][17]*

| Histologic feature | Chronic telogen effluvium | Implication |
| --- | --- | --- |
| Anagen:telogen ratio | Approximately 8:1 versus 14:1 in normal scalp. [17] | Supports increased telogen representation in the appropriate clinical setting. [17] |
| Terminal:velluslike ratio | Approximately 9:1 in one chronic telogen effluvium series. [5] | Preserved terminal predominance helps distinguish from miniaturizing androgenetic alopecia. [5][17] |
| Follicular miniaturization | Not expected in isolated telogen effluvium. [17] | Favors androgenetic alopecia when present. [17] |
| Peribulbar infiltrate | Not expected in uncomplicated telogen effluvium. [17] | Should prompt consideration of an alternate inflammatory or autoimmune alopecia. [17] |

## Treat the trigger, set a realistic recovery timeline, and avoid unsupported routine therapy

Acute telogen effluvium generally requires correction and observation rather than aggressive hair-directed treatment.

For acute telogen effluvium, correct the identified precipitant: treat thyroid disease or other systemic illness, address documented iron or nutritional deficiency, stop or substitute a likely causative medication when clinically safe, and treat concurrent scalp psoriasis or seborrheic dermatitis. If no trigger is found, explain that a cause remains unidentified in approximately one-third of acute cases and schedule reassessment rather than assigning a permanent diagnosis prematurely. [16][17]

Counsel that acute telogen effluvium is usually self-limited. About 95% of acute cases remit in one review, and most patients regain normal fullness within 6-9 months; restoration of baseline thickness can take up to 18 months. Short regrowing frontal hairs on follow-up support recovery. [6][16]

Topical minoxidil has theoretical effects on the hair cycle but has not been proven to promote recovery in telogen effluvium. It may be discussed only as an individualized adjunct, particularly when coexisting androgenetic alopecia is suspected, while explicitly distinguishing this from evidence-based trigger correction. [6][15]

Avoid empiric long-term nutritional supplementation in the absence of a severe or documented deficiency. Nutritional supplements are described as appropriate for severe deficiency and not recommended for long-term routine use; ferritin, zinc, and vitamin D abnormalities may be common in populations with and without chronic telogen effluvium. [2][10]
- Reassess before 6 months if shedding accelerates, pattern loss becomes evident, examination becomes atypical, or a new systemic illness or medication exposure occurs. [3][16]
- At 6 months of ongoing shedding, revisit recurrent triggers and targeted laboratory findings, perform trichoscopy, and consider biopsy if androgenetic alopecia or diffuse alopecia areata remains plausible. [4][13][17]
- Use objective follow-up documentation of shedding burden, distribution, and regrowth rather than relying only on a single hair-count estimate. Hair collections can decline over weeks as telogen effluvium improves. [15]

### Chronic telogen effluvium

Chronic telogen effluvium is defined by diffuse telogen hair loss persisting longer than 6 months and is often fluctuating. Before labeling it primary chronic telogen effluvium, search for repeated or persistent triggers, including nutritional deficiency, thyroid disease, infection, systemic illness, and medications; the longer shedding continues, the more likely multiple or recurrent triggers contribute. [13][17]

When chronic telogen effluvium is confirmed after exclusion of competing causes, prioritize expectation-setting and longitudinal assessment. Chronic disease has a different prognosis from androgenetic alopecia, so confirming the diagnosis with trichoscopy or biopsy when uncertain prevents unnecessary or misdirected long-term therapy. [3][4]

*Management and monitoring by course. [6][13][16][17]*

| Course | Immediate action | Monitoring and escalation |
| --- | --- | --- |
| Acute shedding <6 months with a clear trigger | Remove or treat the trigger; replace or discontinue a suspected culprit drug when safe. [16][17] | Expect improvement over months; reassess if the trajectory is not improving or a competing alopecia becomes apparent. [6][16] |
| Acute shedding without an identified trigger | Use targeted history, examination, and testing for reversible systemic, thyroid, iron, and nutritional causes. [12][16] | Reevaluate rather than assuming a fixed chronic disorder; about one-third of acute episodes have no identified cause. [16] |
| Persistent shedding >6 months | Reassess repeated triggers, medications, systemic disease, and nutritional exposures. [13][17] | Use trichoscopy and biopsy when androgenetic alopecia or diffuse alopecia areata remains uncertain. [3][4][17] |
| Concurrent patterned thinning or histologic miniaturization | Treat as possible coexisting androgenetic alopecia rather than attributing all loss to telogen effluvium. [3][17] | Track pattern progression separately from resolution of shedding. [3][24] |

## Common questions

### Is a ferritin target required before telogen effluvium will recover?

No universal ferritin target for hair recovery is established. Ferritin helps identify iron deficiency, but proposed thresholds vary: one study used >40 micrograms/L as desirable, whereas others have considered >15 micrograms/L sufficient. Treat documented deficiency and its cause rather than pursuing indefinite empiric supplementation. [10][12][18]

### When should topical minoxidil be offered for telogen effluvium?

Do not present topical minoxidil as required treatment for acute telogen effluvium; it has theoretical benefit but has not been proven to accelerate recovery. Consider individualized discussion when concomitant androgenetic alopecia is suspected, while continuing trigger-directed care. [6][15]

## References
1. Oral Minoxidil vs Topical Minoxidil for Male Androgenetic Alopecia — jamanetwork.com — https://jamanetwork.com/journals/jamadermatology/fullarticle/2817326
2. Nutritional Supplements and Hair Loss—Limitations ... - JAMA Network — jamanetwork.com — https://jamanetwork.com/journals/jamadermatology/articlepdf/2806310/jamadermatology_obijiofor_2023_le_230001_1692117352.46104.pdf?resultClick=1
3. Telogen Effluvium – a review of the science and current obstacles — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0923181121000086
4. CHRONIC TELOGEN EFFLUVIUM - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0733863505703983
5. Chronic telogen effluvium: Increased scalp hair shedding in middle-aged women - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0190962296901139
6. Covid Induced Telogen Effluvium (CITE) : Indian Dermatology Online Journal — journals.lww.com — https://journals.lww.com/idoj/fulltext/2022/13040/covid_induced_telogen_effluvium__cite___an_insight.1.aspx
7. Alopecia in general medicine - ScienceDirect.com — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S1470211824027490
8. Chronic diffuse alopecia in women: a retrospective review of ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/full/10.1111/ijd.16921
9. Use of 5% Topical Minoxidil Application for Telogen Effluvium: An ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1111/1346-8138.17844
10. Chronic telogen effluvium in women : Journal of the Egyptian Women's Dermatologic Society — journals.lww.com — https://journals.lww.com/jewds/_layouts/15/oaks.journals/downloadpdf.aspx?an=01287624-202118030-00008
11. Role of ferritin, vitamin D, and thyroid... : Al-Azhar Assiut Medical Journal — journals.lww.com — https://journals.lww.com/aamj/_layouts/15/oaks.journals/downloadpdf.aspx?an=01157422-202119030-00015
12. An Analytical Study of Serum Ferritin, Vitamin D, and Thyroid ... — journals.lww.com — https://journals.lww.com/ijdd/fulltext/2022/09010/an_analytical_study_of_serum_ferritin%2C_vitamin_d%2C.2.aspx
13. Systematic approach to hair loss in women - Trüeb - 2010 - JDDG — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1111/j.1610-0387.2010.07261.x
14. Telogen effluvium related to post severe Sars‐Cov‐2 infection ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1111/dth.14547
15. Telogen Effluvium - StatPearls - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/portal/utils/pageresolver.fcgi?recordid=696c5ba7dc96372a6deae059
16. Telogen Effluvium: A Review of the Literature - PMC — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7320655
17. Telogen Effluvium: A Review of the Literature — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7320655
18. The Diagnostic Value of Serum Ferritin for Telogen Effluvium: A Cross-Sectional Comparative Study - PMC — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7882421
19. C1 PAGE.indd - AAP Publications — publications.aap.org — https://publications.aap.org/pediatricsinreview/issue-pdf/828505
20. Comparative evaluation of two Unani formulation combinations in the treatment of telogen effluvium: A randomized, single-blind clinical trial - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S2097382926000107
21. Male Type Alopecia - an overview — www.sciencedirect.com — https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/male-type-alopecia
22. Low-dose oral minoxidil beyond androgenetic alopecia — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S2950198926000589
23. Systematic review: Impact of stem cells-based therapy, and platelet ... — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S2352320423000652
24. Dengue-associated telogen effluvium: A report of 14 patients — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S1027811716301604

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.